Member Info for potnak

There is an image here https://www.fortyseveninc.com/science#CD47
Where it says amplifies the efficacy of CHK1 inhibitors.

For me, it's too big a coincidence that Gilead are trying to buy a company that is developing a compound that could enhance the efficacy of CHK1 inhibitors which they also have a stake in. We'll have to see how this pans out but I believe we have our (or sierra does) funding for SRA737. And The quicker we get to a milestone trigger the better.

Amplifies the efficacy of checkpoint inhibitors.

Are you all in the pub? ha ha. I think this news confirms what some already thought and gives us a good idea why Gilead took a stake in Sierra. and it's not for Momentum.

So yes then. Next week might be interesting after all.

Interesting. Is there a crossover with SRA737 and Forty Seven's P1 Ovarian offering? Fadec is probably scouring the data as I type :-)

i can't see anything bad. either they will find funding, good for SAR. or they won't get funding and we take it back. also good for SAR. The bad thing for SAR is the not knowing. Bring it on.

To be fair BP, they wouldn't change that statement until after the news is announced. However. This does sound like an update for Momentum rather than a company update.

We're not going down the pan. It might get worse before it gets better though. if there was a placing. I'd take part in it this time or at least buy when the news hits. Few pieces of the jigsaw to put in place before cashing out and we only need one of them for it all to kick off. GLA

Again, I'm not really being negative. If posters genuinely believe there is going to be another raise and some bad news. Why don't they sell? I'd hazard a guess that the board will already know if they need to raise or not. Only they know what discussions are currently ongoing and when something if anything could happen. If they do need to raise. They'll probably wait on Sierra's report. If we get a bit of a lift on the back of it. They'll hit us with a placing. I think we will need to raise but I haven't got the balls to sell because we could easily see 3 x today's SP if the report is good and it states how SRA737 will be funded. I'm holding on tight, same as most others here. Lets face it. We havn't got long to wait. GLA

You may be correct Utar. But on that thinking, why not just get out now? A raise would likely see us at 0.2 again! So again, why don't you sell now? It isn't a trick question.

I finally start getting 2 + 2 = 4 then Thoth throws this in. Maybe 2 + 2 does = 28P :-)

I was expecting the next news to be the about the patent but that has now been delayed again. Tim said value in 12 months approx 9 months ago. He's been burnt before with his predictions so I firmly believe there is something coming or he wouldn't have said it. Will he meet the deadline he set? I don't know.

I might come across as negative, i'm not i'm still bullish about SAR. The only reservations I have is the funding thing, will we get funding before we have to raise again? and that our compounds are just OK. I honestly believe if they were blockbusters we'd have a deal already. I think we are going to have to wrestle them through the trials and over the line which is fine as long as there is a steady rise in SP and we are funded.

Aber - I absolutely feel your pain. And your feeling that if our compounds were that good, we'd already have a deal. I still think we'll get more than 3p on sentiment and dumb money. I d just rather we let the market decide rather than sell on the cheap.

My main issue with a low offer like that would be In the 8 years or so I've been invested risky SAR. I could have got that kind of return in much less risky investments. I have a wealth manager friend who still states that I could get a 50% return over 3 years if I except some risk. I've another friend who on average has been making 18% a year for the last 5 years on a £100k investment. If she had put in in SAR. she'd only have £50k now. I don't want to lose but I'd be unhappy with anything less than 3p and that was always my low target.

Sarimmunupharma?

This is what I'm thinking but feel we are going to back down and give them some slack re the milestones. Do you think it will be announced this month with the quarterly news? They have to say something about SRA737.

I've given up trying to work out what's happening over the pond. Two scenarios both with complex solutions. 1 SRA737 is good and they won't give it up without a fight. 2. SRA737 is bad and we get it back. Something has got give somewhere.

I don't think I'm being negative. Pragmatic, more like. We are where we are. If SRA737 was dead cert blockbuster. Sierra would already have a stonking deal. IMO, I don't think it is a dead cert so the deal will reflect the risk still ahead. Personally, unless I see data to make me hang around. I'll have cashed in before a fail or getting to market. I'm getting quite excited about TYK2. If we could get to 1p before a deal is announced we might see a nice spike for me to bail out on. I suspect I'm more aligned with Utar than most others here. He's realist, so am I. The is data is out there for all our compounds if they were dead certs, we'd already be sitting on a beach in the Bahamas. All we need is some good data and some dumb money to pile in. Wish for dumb money, not science.

I still believe we'll get something from CHK1 but I'm not convinced it is as good as we think it is. IMO, the data is probably luke warm rather than hot. Think Sierra will get an on license which will give us a lift but I'm pinning my hopes on TYK2 and hopefully we'll be cashing out before SRA737 has a chance to fail a p3. Either this or BA has the best poker face ever.